Search Back New search Go to resultsDiseaseMain groupHematological Diseases, Non-MalignantProtocol groupAnemias, CytopeniasHemolytic DiseasesDiseaseParoxysmal Nocturnal HemoglobinuriaSubgroupICD10D59.5MeSHHemoglobinuria, ParoxysmalSequenceChemotherapyChemo-substanceEculizumabPegcetacoplanRavulizumabChemo-substanceEculizumabPegcetacoplanRavulizumabChemo-substanceEculizumabPegcetacoplanRavulizumabChemo-substanceEculizumabPegcetacoplanRavulizumabNo. Substances1 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionSupportive substanceBalanced Crystalloid SolutionSupportive substanceBalanced Crystalloid SolutionSupportive substanceBalanced Crystalloid SolutionNo. Substances1Protocol classificationTherapy classificationcurrent standardIntensityStandard doseTherapy indicationFirst lineSecond lineseveral possibleTherapy phaseInductionMaintenanceTherapy intentiondisease controlRisksAnemia Hb below 10g/dlArthalgiaAstheniaConstipationDiarrheaFatigueHeadacheHematotoxicityNasopharyngitisNauseaPainPyrexiaRashUpper Respiratory Tract InfectionVomiting only studiesPublicationAuthorHillmen PLee J / Kulasekararaj ADiseasemind. 4 vorangegeangene Transfusionen in den letzten 12 Monaten, mind. 10% PNH Zellen und 100.000 Thrombozyten/µlmind. 4 vorangegegangene Transfusionen in den letzten 12 Monaten, mind. 10% PNH Zellen und 100.000 Thrombozyten/µlPNH, Erst-oder Zweitlinie nach EculizumabPNH mit Hämoglobin < 10,5g/dl während 3 Monaten EculizumabOrigin301/302 studyBexley Wing, St. James’s University Hospital, Leeds, United Kingdom, Pegasus trialLeeds General Infirmary, Leeds, United Kingdom, TRIUMPHProtocols in Revision 5 protocols foundProtocols under revision.Eculizumab 600, Paroxysmal Nocturnal Hemoglobinuria, Induction (PID791)Eculizumab 900, Paroxysmal Nocturnal Hemoglobinuria, maintenance (PID792)Pegcetacoplan 1080, Paroxysmal Nocturnal Hemoglobinuria (PID1928)Ravulizumab 2700, Paroxysmal Nocturnal Hemoglobinuria, Induction (PID1449)Ravulizumab 3300, Paroxysmal Nocturnal Hemoglobinuria, maintenance (PID1450)